* Cross Country Healthcare Inc CCRN.OQ CCRN.O is
expected
to show a fall in quarterly revenue when it reports results on
July 31 for the period ending June 30 2024
* The Boca Raton Florida-based company is expected to
report a
38.1% decrease in revenue to $334.759 million from $540.7
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.The company's guidance on May 1
2024, for the period ended June 30, was for revenue between
330.00 million and 340.00 million.
* LSEG's mean analyst estimate for Cross Country Healthcare
Inc
is for earnings of 13 cents per share. The company's EPS
guidance on May 1 2024, for the period ended June 30, was
between 0.10 and 0.20
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cross
Country
Healthcare Inc is $18.50, above its last closing price
of $16.52.
The company's guidance on May 1 2024 for the period ended June
30 was for Earnings before Interest, Taxes, Depreciation and
Amortization of between 330 million and 15 million.The company's
guidance on May 1 2024 for the period ended June 30 was for
gross profit margin between 21% and 21.5%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 0.17 0.17 0.19 Beat 10.9
Dec. 31 2024 0.27 0.27 0.29 Beat 6.1
Sep. 30 2023 0.41 0.41 0.39 Missed -4.2
Jun. 30 2023 0.61 0.61 0.69 Beat 13.3
Mar. 0.75 0.75 0.84 Beat 12.4
31 2023
Dec. 31 2022 0.89 0.89 1.09 Beat 21.9
Sep. 30 2022 0.96 0.95 1.07 Beat 12.6
Jun. 30 2022 1.35 1.35 1.40 Beat 3.8
This summary was machine generated July 29 at 20:48 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)